MURA MURAL ONCOLOGY PUB LTD CO

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at . A replay of the webcast will be archived and available following the event.

About Mural Oncology

Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. Our lead candidate, nemvaleukin alfa, is currently in potentially registrational trials in platinum-resistant ovarian cancer and mucosal melanoma reading out in late Q1/early Q2 and Q2 of 2025, respectively. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at  and follow us on  and . 

Contact:

Katie Sullivan



EN
18/02/2025

Underlying

MURAMURAL ONCOLOGY PUB LTD CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MURAL ONCOLOGY PUB LTD CO

 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Co...

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the “Effective...

December 5, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Sanction of the Scheme by the High Court

Mural Oncology Announces Sanction of the Scheme by the High Court WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), will acquire the entire issued and to be issued share capital of Mural (the “Acquisition”). The Scheme and...

December 3, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Final Cash Consideration Payable on Closing o...

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), XRA 5 Corp. (“Sub”) and Mural announced on August 20, 2025 (the “Transaction Agreement”), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction A...

November 26, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces that Mural Shareholders Approve the Proposed ...

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION  WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. (“Sub”)...

October 24, 2025 1 EN
 PRESS RELEASE
Free
MURA MURAL ONCOLOGY ...

Mural Oncology Announces Commencement of Mailing of Definitive Proxy S...

Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the “Irish Takeover Rules”), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the “P...

September 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch